Parry Nutraceuticals' receives US-FDA approval

Parry Nutraceuticals, a division of EID Parry and part of diversified business conglomerate Murugappa Group, has received the US Food and Drug Administration approval for its India facility to develop organic microalgae cultivation, the company said today.
The fully organic 130 acre 600 TPA facility in Pudukottai district in Tamil Nadu has received the Establishment Inspection Report from the US-FDA, a company statement said.
The approval from the US-FDA comes after an an inspection of the facility in July 2016.
"We are proud of this result, as it is a testament to our on-going commitment to maintaining superior quality systems", Parry Neutraceuticals Business-Head, Muthu Murugappan said.

"We are a preferred supplier of micro-algal health supplements for several leading nutraceutical brands in over 35 countries. This approval will further enhance our reputation as a leader in micro-algal technology", he said.
Noting that the company was enhancing new product development to meet customer demand, he said, "our new product strategy is to provide value addition to our existing micro-algal range".
Some of the products that would be introduced over the next two years include organic chlorella, spirulina granules, extracted Lutein, he added.